– Ed Arce, H.C. Wainwright & Co.
|"I wanted to send out a quick update on DXD after two tremendous announcements last week that I believe the market totally missed, which is where we see a major buying opportunity."|
|"RP announced that it has identified two new two European manufacturers with which it will collaborate going forward on development of its patented Pelletier element cooled dermal injector RCI-02."|
|"INO's revenues and R&D were slightly above our projections."|
|"RP has successfully completed its first-in-human clinical study of the company's autologous cell therapy for the treatment of androgenetic alopecia."|
|"DRRX provided a 4Q16 earnings update and indicated that they are actively working towards commencing a Phase 2 trial with an oral formulation of DUR-928 for PSC."|
|"INO's VGX-3100 study should start in 1H17, multiple catalysts ahead in other programs."|